James W. Cooper, RPh,PhD, BCPS, CGP, FASCP, FASHP, FCP, Emeritus Professor of Pharmacy, UGa and Consultant Pharmacist NOTE: Dr.J. Russell May of GHSU and.
Statins in the Primary and Secondary Prevention of CAD Prof. M. Ishaq Karachi Institute of Heart Diseases.
Disclosures / Conflicts of Interest Alfred K. Cheung, M.D. None relevant to this topic.
SLIDES FOR NDA 21-213 ADVISORY COMMITTEE PRESENTATION.
Aggressive Lipid Lowering Treatment
SLIDES FOR NDA 21-213 ADVISORY COMMITTEE PRESENTATION
Background
The State of Dyslipidemia Treatment USA-145-101385 © 2014 Amgen Inc. All rights reserved. Not for Reproduction.
The LAPLACE-2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy.
LIPID LOWERING IN T2D (The Lower the Better?) CONS… TARGETING HARD CVD END POINTS Charles SAAB MD Consultant Endocrinologist DCRP Sacre-Coeur University.
Dov Gavish MD הטיפול בחולים בסיכון גבוה לאור המלצות ESC2011-2012 מאי 2013 ההסתדרות הרפואית בישראל – החברה לחקר, מניעה
